Financings Of The Fortnight: Is Venture Capital's Glass Half-Full Or Half-Empty?
This article was originally published in The Pink Sheet Daily
Fundraising successes by Trevena, Sunesis, Calithera and iPierian highlight the last two weeks' action.
You may also be interested in...
Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.